Dawson James Securities provides analyst coverage on multiple companies in the biotech, healthcare, technology and clean tech space. Our analysts have appeared on national TV, financial media, scientific publications and mass media.

Members of the Department have been recognized as authorities on oncology drugs, stem cells, gene therapy, drug delivery, cardiovascular, orthopedic therapeutics and devices and their expertise has been sought by CEOs and Boards of Directors.

Our research helps to provide our clients the confidence to make rational investment decisions in the complex fast-moving micro-cap environment with a focus on healthcare.